Version history

{
  "session_id": "sess_hypdebate_h_9d29bfe5_20260427_161728",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "content": "\n\n## Practical and Translational Assessment: Membrane Cholesterol Gradient Modulators\n\n### Druggability Analysis\n\nThe three nodes—ABCA1, LDLR, and SREBF2—present variable tractability. SREBF2, as a transcription factor, is notoriously difficult to target with small molecules; while compounds like **fatostatin** (Sigma-Aldrich) inhibit SREBP processing in vitro, no CNS-penetrant clinical candidate exists. ABCA1 modulators (e.g., **avasimibe**, **implitapide**) have been explored but face challenges: peripheral upregulation causes hepatomegaly and lipogenesis—exactly the toxicity that derailed LXR agonists. LDLR is more tractable via monoclonal antibodies (evolocumab, alirocumab), but these biologics don't cross the blood-brain barrier.\n\n**Best tractable approach**: Indirect upregulation of ABCA1 via LXR agonism, though this class has stalled due to"
}